MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53

BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly aggressive tumour that is first-line treated with a combination of cisplatin and pemetrexed. Until now, predictive and prognostic biomarkers are lacking, making it a non-tailored therapy regimen with unknown outcome. P53 is frequently inac...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Cancer
Egile Nagusiak: Walter, R F H, Mairinger, F D, Ting, S, Vollbrecht, C, Mairinger, T, Theegarten, D, Christoph, D C, Schmid, K W, Wohlschlaeger, J
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2015
Gaiak:
Molecular Diagnostics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453955/
https://ncbi.nlm.nih.gov/pubmed/25668009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.27
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak